Diamyd Medical AB
DMYD-B.STDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®
Type 1 Diabetes Mellitus
Diamyd
Diabetes Mellitus, Type 1
rhGAD65 formulated in Alhydrogel® (Diamyd®)
Latent Autoimmune Diabetes in Adult (LADA)
NP2
Intractable Pain
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel® | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Diamyd | Phase 2 | Diabetes Mellitus, Type 1 | - | - |
rhGAD65 formulated in Alhydrogel® (Diamyd®) | Phase 2 | Latent Autoimmune Diabetes in Adult (LADA) | - | - |
NP2 | Phase 2 | Intractable Pain | - | - |
Frequently asked questions
What is in Diamyd Medical AB's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Diamyd Medical AB's (DMYD-B.ST) pipeline across Phase 3, Phase 2. Its lead program is Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel® (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Diamyd Medical AB's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Diamyd Medical AB (DMYD-B.ST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track DMYD-B.ST biotech catalysts?→
Add DMYD-B.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Diamyd Medical AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.